NCT06245122 2026-04-06
A Study of CS23546 in Subjects With Advanced Tumors
Chipscreen Biosciences, Ltd.
Phase 1 Recruiting
Clinical Trials
17 trialsNCT07110584 2026-03-05
Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors
ModeX Therapeutics, An OPKO Health Company
Phase 1/2 Recruiting
NCT07205198 2026-01-08
A Clinical Trial of SIBP-A10 Injection in the Treatment of Advanced Malignant Tumor Subjects.
Shanghai Institute Of Biological Products
Phase 1 Recruiting
NCT07179081 2025-09-17
A Study of AL58805 in Patients With Advanced Tumors
Advenchen Laboratories, LLC
Phase 1 Recruiting
NCT03444714 2025-09-15
Phase I Study of RiMO-301 With Radiation in Advanced Tumors
Coordination Pharmaceuticals, Inc.
Phase 1 Completed
NCT05429008 2025-06-18
A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm
Hutchmed
Phase 1 Completed
NCT06314087 2025-03-25
Individualized Neoantigen Therapy with Unusual Radiotherapy Enhancement (iNATURE)
The University of Hong Kong-Shenzhen Hospital
Phase 2 Recruiting
NCT05799183 2024-12-31
A SHR-1210 BE Study on Healthy Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Terminated
NCT04151810 2024-08-27
Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors
Dragonboat Biopharmaceutical Company Limited
Phase 1 Completed
NCT05068856 2024-07-18
A Study of HRS2543 in Patients With Advanced Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1 Terminated
NCT04808453 2024-02-07
CPI-300
Coordination Pharmaceuticals, Inc.
Phase 1 Completed
NCT05867771 2023-05-22
A Study of PM1022 in Patients With Advanced Tumors
Biotheus Inc.
Phase 1/2 Unknown
NCT03781362 2022-07-20
Study of CPI-100 in Patients With Advanced Tumors
Coordination Pharmaceuticals, Inc.
Phase 1 Completed
NCT02419417 2022-06-16
BET
Bristol-Myers Squibb
Phase 1/2 Completed
NCT05213767 2022-01-28
Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT05061628 2021-09-29
The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Unknown
NCT03908814 2019-10-31
Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors
Dragonboat Biopharmaceutical Company Limited
Phase 1 Unknown